Most Recent Additions*
Providing Skilled Mentorship for a Newly Forming Research and Evidence-Based Practice (EBP) & Education Council
Bedane Geleta, Gale Springer, and So Young Pak
Phase 1b study of dazostinag plus pembrolizumab after hypofractionated radiotherapy in patients with non-small-cell lung cancer, triple-negative breast cancer, or head and neck squamous-cell carcinoma
BT Cooper, David Page, and See full list of authors in comments
Role of GLP-1 and GIP/GLP-1 Receptor Agonists in Management of
Cardiovascular-Kidney-Metabolic (CKM) Conditions
Radica Alicic and JJ Neumiller
Transforming CKD Care from Evidence Generation to Implementation
Katherine Tuttle
Treatment of Chronic Kidney Disease and Heart Failure Circa 2024
Katherine Tuttle
The FLOW Trial of Semaglutide for CKD in Type 2 Diabetes: Kidney, Cardiovascular, and Mortality
Outcomes
Katherine Tuttle
Journal names its 25 People of Influence in 2025
Katherine Tuttle (author mention)
“How GLP1 receptor agonist evolved from weight management drug to kidney protective therapy”
Katherine Tuttle
Artificial intelligence VS human pathology
Carlo Bifulco
Rinatabart Sesutecan For Patients With Heavily Pretreated Ovarian Or Endometrial Cancer: Results From The Dose Escalation Cohort Of A Phase 1/2 Study
Justin Call, Ian Anderson, and See full list of authors in comments
Is Perioperative Immunotherapy the New Standard of Care
Rachel Sanborn
Validation of a Homologous Recombination Deficiency (HRD) Assay for Use in Combination with Comprehensive Genomic Profiling (CGP) Testing
J Welle, Brian Piening, Carlo Bifulco, and See full list of authors in comments
Updated results from a phase 1 study of evalstotug (BA3071), an anti–CTLA-4 conditionally active biologic, with or without nivolumab, in advanced solid tumorsv
J Thomas, Matthew Taylor, and See full list of authors in comments
*Updated as of 04/28/25.
